Edgewise Therapeutics moves heart disease drug into Phase 3 after updated Phase 2 data
read at Endpoints ↗Positive readoutPositive
Edgewise Therapeutics announced on June 16, 2026 that it will advance its investigational therapy for a genetic heart disease into a registrational Phase 3 trial.
The decision follows an updated analysis of its Phase 2 study, which the company says supports moving forward with a larger efficacy study.
The move positions Edgewise to seek regulatory approval pending successful Phase 3 results, reflecting continued progress in its cardiovascular pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Edgewise to advance heart drug into Phase 3 following mid-stage data update”
read at Endpoints ↗83 words · retrieved Jun 16
comments(0)
5-min edit window · permanent after that